公开(公告)号：EP1981909B1

公开(公告)日：2016-10-12

申请号：EP07763514.2

申请日：2007-02-08

申请人： Morphotek, Inc.

发明人： SASS, Philip M. ,  NICOLAIDES, Nicholas C. ,  GRASSO, Luigi ,  LI, Jian ,  CHAO, Qimin ,  ROUTHIER, Eric ,  EBEL, Wolfgang

IPC分类号： C07K16/24

CPC分类号： C07K16/243 ,  A61K39/395 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/22 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/09 ,  C12N15/63

摘要： The present invention provides a recombinantly expressed human monoclonal antibody that specifically binds to granulocyte macrophage colony stimulating factor (GM-CSF) wherein said antibody comprises a heavy chain comprising a CDR1 of SEQ ID NO: 46, a CDR2 of SEQ ID NO: 47, and a CDR3 of SEQ ID NO: 48 and a light chain comprising a CDR1 of SEQ ID NO: 49, a CDR2 of SEQ ID NO: 50, and a CDR3 of SEQ ID NO: 51.

公开(公告)号：EP2635304A2

公开(公告)日：2013-09-11

申请号：EP11785862.1

申请日：2011-11-04

申请人： Morphotek, Inc.

发明人： O'SHANNESSY, Daniel, J. ,  GRASSO, Luigi ,  WAN, Shanhong ,  CHAO, Qimin ,  SOMERS, Elizabeth, Brooke

IPC分类号： A61K39/395 ,  G01N33/574 ,  G01N33/82

CPC分类号： G01N33/57423 ,  A61K39/395 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/82 ,  G01N2800/52 ,  G01N2800/56

摘要： The present invention provides methods and kits for assessing whether a subject is afflicted with an FRα-expressing cancer, methods and kits for predicting the progression of ovarian cancer in a subject afflicted with an FRα-expressing cancer, methods and kits for assessing the level of risk that a subject will develop an FRα- expressing cancer, and methods of stratifying a subject with an FRα-expressing cancer into cancer therapy groups. The methods involve determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject and comparing this level with the level of FRα in a control sample.

公开(公告)号：EP1476577B1

公开(公告)日：2009-04-15

申请号：EP03733833.2

申请日：2003-02-21

申请人： Morphotek, Inc.

发明人： GRASSO, Luigi ,  NICOLAIDES, Nicholas, C. ,  SASS, Philip, M.

IPC分类号： C12Q1/68 ,  C12N15/85

CPC分类号： C12N15/1024 ,  C12N15/85 ,  C12N2830/42 ,  C12N2840/203

摘要： The present invention features mammalian expression vectors that are useful for controlling DNA hypermutability in mammalian cell as well as the encoding polynucleotide sequences of vector sequences. In related aspects the invention features expression vectors and host cells comprising such polynucleotides. In other related aspects, the invention features transgenic cells expressing a mutator gene to enhance genome-wide mutagenesis, due to, for example, the presence of an exogenous mutator-encoding polynucleotide sequence. Further, the invention provides methods for using vector sequences that can remove the expression of such gene to restore DNA stability in a host cell.

公开(公告)号：EP2013620A2

公开(公告)日：2009-01-14

申请号：EP07760710.9

申请日：2007-04-16

申请人： Morphotek, Inc.

发明人： KLINE, J., Bradford ,  CHAO, Qimin ,  SASS, Philip M. ,  GRASSO, Luigi ,  NICOLAIDES, Nicholas C.

IPC分类号： G01N33/50

CPC分类号： C12N15/01 ,  C12N15/1024 ,  C12N15/1079

摘要： Whole Genome Evolution Technology can be considered a broad tool for supporting the needs for scaleable manufacturing of therapeutic antibodies. Its random nature and in vivo mode of action separate this process from other complementary technologies, thus providing alternative solutions to improve a host cell's manufacturing performance. The speed with which a pre-existing production strain can be optimized makes this process suitable for satisfying the current need for rapid cell line optimization to produce faster growing cells exhibiting high titers of antibody at the preclinical, clinical or commercialization stage.

公开(公告)号：EP1363930B1

公开(公告)日：2006-08-16

申请号：EP00978578.3

申请日：2000-11-14

申请人： Morphotek Inc.

发明人： NICOLAIDES, Nicholas, C. ,  GRASSO, Luigi ,  SASS, Philip, M.

IPC分类号： C07K14/47 ,  A61K39/00 ,  C12N15/00 ,  C12N15/63 ,  C12N15/85

CPC分类号： C07K14/47 ,  A61K39/00 ,  C07K2319/00

摘要： Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within genes encoding for therapeutic antigens to produce altered polypeptides with enhanced antigenic and immunogenic activity. Moreover, these methods are useful for generating effective vaccines.

公开(公告)号：EP1556508A2

公开(公告)日：2005-07-27

申请号：EP03754530.8

申请日：2003-09-12

申请人： Morphotek Inc. ,  Nicolaides, Nicholas E. ,  Sass, Philip, M.

发明人： GRASSO, Luigi

IPC分类号： C12Q1/68 ,  C07K16/00

CPC分类号： C12N15/01 ,  C07K16/00 ,  C07K16/4291 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/92 ,  C12N15/1024

摘要： Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulins genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. The invention also provides methods for increasing the affinity of monoclonal antibodies and monoclonal antibodies with increased affinity.

公开(公告)号：EP1351565A1

公开(公告)日：2003-10-15

申请号：EP01901992.6

申请日：2001-01-15

申请人： Morphotek Inc.

发明人： NICOLAIDES, Nicholas, C. ,  GRASSO, Luigi ,  SASS, Philip, M.

IPC分类号： A01H1/06 ,  A61K31/7076 ,  A61K31/7088 ,  C12N1/00 ,  C12N5/00 ,  C12Q1/68

CPC分类号： C12N15/1024 ,  A01H3/04 ,  C12N15/01 ,  C12N15/8212 ,  G01N33/5014 ,  G01N33/5088

摘要： Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. Methods of generating mutations in genes of interest and of making various cells mismatch repari defective through the use of chemicals to block mismatch repari in in vivo are disclosed.

公开(公告)号：EP3130605A1

公开(公告)日：2017-02-15

申请号：EP16186634.8

申请日：2011-11-04

申请人： Morphotek, Inc.

发明人： O'SHANNESSY, Daniel J. ,  GRASSO, Luigi ,  WAN, Shanhong ,  CHAO, Qimin ,  SOMERS, Elizabeth Brooke

IPC分类号： C07K16/28 ,  G01N33/574 ,  G01N33/82

摘要： The present invention provides methods and kits for assessing whether a subject is afflicted with an FRα-expressing cancer, methods and kits for predicting the progression of ovarian cancer in a subject afflicted with an FRα-expressing cancer, methods and kits for assessing the level of risk that a subject will develop an FRα-expressing cancer, and methods of stratifying a subject with an FRα-expressing cancer into cancer therapy groups. The methods involve determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject and comparing this level with the level of FRα in a control sample.

摘要翻译： 本发明提供用于评估受试者是否患有FR±表达的癌症的方法和试剂盒，用于预测患有FR±表达的癌症的受试者的卵巢癌进展的方法和试剂盒，用于评估 受试者将发展FR表达的癌症的风险水平，以及将具有FR±表达的癌症的受试者分层为癌症治疗组的方法。 该方法涉及确定不受来自受试者的样品中细胞的叶酸受体α（FR±）的水平，并将该水平与对照样品中的FR±水平进行比较。

公开(公告)号：EP2310416A1

公开(公告)日：2011-04-20

申请号：EP09774273.8

申请日：2009-06-30

申请人： Morphotek, Inc.

发明人： NICOLAIDES, Nicholas, C. ,  SASS, Philip, M. ,  GRASSO, Luigi ,  EBEL, Wolfgang ,  ROUTHIER, Eric ,  YAO, Jun ,  ZHOU, Yuhong ,  ZUO, Xun

IPC分类号： C07K16/30 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/3084 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

摘要： Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.

公开(公告)号：EP1351565B1

公开(公告)日：2011-03-16

申请号：EP01901992.6

申请日：2001-01-15

申请人： Morphotek, Inc.

发明人： NICHOLAIDES, Nicholas, C. ,  GRASSO, Luigi ,  SASS, Philip, M.

IPC分类号： A01H1/06 ,  A61K31/7076 ,  A61K31/7088 ,  C12N1/00 ,  C12N5/00 ,  C12Q1/68

CPC分类号： C12N15/1024 ,  A01H3/04 ,  C12N15/01 ,  C12N15/8212 ,  G01N33/5014 ,  G01N33/5088

摘要： Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. Methods of generating mutations in genes of interest and of making various cells mismatch repari defective through the use of chemicals to block mismatch repari in in vivo are disclosed.